Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Proceeds to be used to continue to advance rigorously designed clinical trials of Armata’s high purity phage-based therapeutic candidates LOS ANGELES, March 4, 2024 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks